This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
DeAngelis LM. Brain tumors. N Engl J Med 2001; 344: 114-23.DeAngelisLMBrain tumorsN Engl J Med20013441142310.1056/NEJM20010111344020711150363Search in Google Scholar
Buckner JC. Factors influencing survival in high-grade gliomas. Semin Oncol 2003; 30(Suppl 19): 10-4.BucknerJCFactors influencing survival in high-grade gliomasSemin Oncol200330Suppl 1910410.1053/j.seminoncol.2003.11.03114765378Search in Google Scholar
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.StuppRMasonWPvan den BentMJWellerMFisherBTaphoornMJet alRadiotherapy plus concomitant and adjuvant temozolomide for glioblastomaN Engl J Med20053529879610.1056/NEJMoa04333015758009Search in Google Scholar
Smrdel U, Kovac V, Popovic M, Zwitter M. Glioblastoma patients in Slovenia from 1997 to 2008. Radiol Oncol 2014; 48: 72-9.SmrdelUKovacVPopovicMZwitterMGlioblastoma patients in Slovenia from 1997 to 2008Radiol Oncol20144872910.2478/raon-2014-0002390885124587783Search in Google Scholar
Hartmann C, Hentschel B, Simon M. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res 2013; 19: 5146-57.HartmannCHentschelBSimonMLong-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutationsClin Cancer Res20131951465710.1158/1078-0432.CCR-13-001723918605Search in Google Scholar
Grabowski MM, Recinos PF, Nowacki AS, Schroeder JL, Angelov L, Barnett GH, et al. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J Neurosurg 2014; 121: 1115-23.GrabowskiMMRecinosPFNowackiASSchroederJLAngelovLBarnettGHet alResidual tumor volume versus extent of resection: predictors of survival after surgery for glioblastomaJ Neurosurg201412111152310.3171/2014.7.JNS13244925192475Search in Google Scholar
Chaichana KL, Cabrera-Aldana EE, Jusue-Torres I, Wijesekera O, Olivi A, Rahman M, et al. When gross total resection of a glioblastoma is possible, how much resection should be achieved? World Neurosurg 2014; 82: e257-65.ChaichanaKLCabrera-AldanaEEJusue-TorresIWijesekeraOOliviARahmanMet alWhen gross total resection of a glioblastoma is possible, how much resection should be achieved?World Neurosurg201482e2576510.1016/j.wneu.2014.01.01924508595Search in Google Scholar
Vecht CJ, Avezaat CJ, van Putten WL, Eijkenboom WM, Stefanko SZ.The influence of the extent of surgery on the neurological function and survival in malignant glioma. A retrospective analysis in 243 patients. J Neurol Neurosurg Psychiatry 1990; 53: 466-71.VechtCJAvezaatCJvanPutten WLEijkenboomWMStefankoSZThe influence of the extent of surgery on the neurological function and survival in malignant glioma. A retrospective analysis in 243 patientsJ Neurol Neurosurg Psychiatry1990534667110.1136/jnnp.53.6.46610142042166137Search in Google Scholar
Valduvieco I, Verger E, Bruna J, Caral L, Pujol T, Ribalta T, et al. Impact of radiotherapy delay on survival in glioblastoma. Clin Transl Oncol 2013; 15: 278-82.ValduviecoIVergerEBrunaJCaralLPujolTRibaltaTet alImpact of radiotherapy delay on survival in glioblastomaClin Transl Oncol2013152788210.1007/s12094-012-0916-x22855197Search in Google Scholar
Sun MZ, Oh T, Ivan ME, Clark AJ, Safaee M, Sayegh ET, et al. Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma. J Neurosurg 2015; 122: 1144-50.SunMZOhTIvanMEClarkAJSafaeeMSayeghETet alSurvival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastomaJ Neurosurg201512211445010.3171/2014.9.JNS1419325768833Search in Google Scholar
Noel G, Huchet A, Feuvret L, Maire JP, Verrelle P, Le Rhun E, et al. Waiting times before initiation of radiotherapy might not affect outcomes for patients with glioblastoma: a French retrospective analysis of patients treated in the era of concomitant temozolomide and radiotherapy. J Neurooncol 2012; 109: 167-75.NoelGHuchetAFeuvretLMaireJPVerrellePLeRhun Eet alWaiting times before initiation of radiotherapy might not affect outcomes for patients with glioblastoma: a French retrospective analysis of patients treated in the era of concomitant temozolomide and radiotherapyJ Neurooncol20121091677510.1007/s11060-012-0883-722660920Search in Google Scholar
Nava F, Tramacere I, Fittipaldo A, Bruzzone MG, Dimeco F, Fariselli L, et al. Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010. Neuro Oncol 2014; 16: 719-27.NavaFTramacereIFittipaldoABruzzoneMGDimecoFFariselliLet alSurvival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010Neuro Oncol2014167192710.1093/neuonc/not316398455524463354Search in Google Scholar
Okita Y, Narita Y, Miyakita Y, Ohno M, Matsushita Y, Fukushima S, et al. IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy. Int J Oncol 2012; 41: 1325-36.OkitaYNaritaYMiyakitaYOhnoMMatsushitaYFukushimaSet alIDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapyInt J Oncol20124113253610.3892/ijo.2012.156422825915Search in Google Scholar
Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol 2014; 16: 81-91.BeikoJSukiDHessKRFoxBDCheungVCabralMet alIDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resectionNeuro Oncol201416819110.1093/neuonc/not159387082324305719Search in Google Scholar
Minniti G, Scaringi C, Arcella A, Lanzetta G, Di Stefano D, Scarpino S, et al. IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. J Neurooncol 2014; 118: 377-83.MinnitiGScaringiCArcellaALanzettaGDiStefano DScarpinoSet alIDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapyJ Neurooncol20141183778310.1007/s11060-014-1443-024748470Search in Google Scholar
van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013; 31: 344-50.vanden Bent MJBrandesAATaphoornMJKrosJMKouwenhovenMCDelattreJYet alAdjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951J Clin Oncol2013313445010.1200/JCO.2012.43.222923071237Search in Google Scholar
Tran AN, Lai A, Li S, Pope WB, Teixeira S, Harris RJ, et al. Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry. Neuro Oncol 2014; 16: 414-20.TranANLaiALiSPopeWBTeixeiraSHarrisRJet alIncreased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetryNeuro Oncol2014164142010.1093/neuonc/not198392251124305712Search in Google Scholar
Molenaar RJ, Verbaan D, Lamba S, Zanon C, Jeuken JW, Boots-Sprenger SH, et al. The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro Oncol 2014; 16: 1263-73.MolenaarRJVerbaanDLambaSZanonCJeukenJWBoots-SprengerSHet alThe combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT aloneNeuro Oncol20141612637310.1093/neuonc/nou005413688824510240Search in Google Scholar
Kalkan R, Atli Eİ, Özdemir M, Çiftçi E, Aydin HE, Artan S, et al. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme. Gene 2015; 554: 81-6.KalkanRAtliEİÖzdemirMÇiftçiEAydinHEArtanSet alIDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiformeGene201555481610.1016/j.gene.2014.10.02725455102Search in Google Scholar
Chen Y, Hu F, Zhou Y, Chen W, Shao H, Zhang Y. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-analysis. Arch Med Res 2013; 44: 281-90.ChenYHuFZhouYChenWShaoHZhangYMGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-analysisArch Med Res2013442819010.1016/j.arcmed.2013.04.00423608672Search in Google Scholar
Iaccarino C, Orlandi E, Ruggeri F, Nicoli D, Torricelli F, Maggi M, et al. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy. Clin Neurol Neurosurg 2015; 132: 1-8.IaccarinoCOrlandiERuggeriFNicoliDTorricelliFMaggiMet alPrognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapyClin Neurol Neurosurg20151321810.1016/j.clineuro.2015.01.029Search in Google Scholar
Weller M, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, et al. MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial. Clin Cancer Res 2015; 21: 2057-64.WellerMTabatabaiGKästnerBFelsbergJSteinbachJPWickAet alMGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trialClin Cancer Res20152120576410.1158/1078-0432.CCR-14-2737Search in Google Scholar
Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1100-8.StuppRHegiMEGorliaTErridgeSCPerryJHongYKet alCilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trialLancet Oncol2014151100810.1016/S1470-2045(14)70379-1Search in Google Scholar
Sibin MK, Bhat DI, Narasingarao KV, Lavanya C, Chetan GK. CDKN2A (p16) mRNA decreased expression is a marker of poor prognosis in malignant high-grade glioma. Tumour Biol 2015; 36: 7607-14.SibinMKBhatDINarasingaraoKVLavanyaCChetanGKCDKN2A (p16) mRNA decreased expression is a marker of poor prognosis in malignant high-grade gliomaTumour Biol20153676071410.1007/s13277-015-3480-5Search in Google Scholar
Boughton B. BRAF and CDKN2A mutations in secondary high-grade glioma. Lancet Oncol 2015; 16: e201.BoughtonBBRAF and CDKN2A mutations in secondary high-grade gliomaLancet Oncol201516e20110.1016/S1470-2045(15)70145-2Search in Google Scholar
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109.LouisDNOhgakiHWiestlerODCaveneeWKBurgerPCJouvetAet alThe 2007 WHO classification of tumours of the central nervous systemActa Neuropathol20071149710910.1007/s00401-007-0243-4192916517618441Search in Google Scholar
Yachi K, Watanabe T, Ohta T, Fukushima T, Yoshino A, Ogino A, et al. Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas. Int J Oncol. 2008; 33: 469-75.YachiKWatanabeTOhtaTFukushimaTYoshinoAOginoAet alRelevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomasInt J Oncol20083346975Search in Google Scholar
Cankovic M, Mikkelsen T, Rosenblum ML, Zarbo RJ. A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue. Lab Invest 2007; 87: 392-7.CankovicMMikkelsenTRosenblumMLZarboRJA simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissueLab Invest200787392710.1038/labinvest.370052017260000Search in Google Scholar
ShahN, SchroederB, CobbsC. MGMT methylation in glioblastoma: tale of the tail. Neuro-Oncology 2015; 17: 167-8.ShahNSchroederBCobbsCMGMT methylation in glioblastoma: tale of the tailNeuro-Oncology201517167810.1093/neuonc/nou319448305825395464Search in Google Scholar
Jeuken J, Cornelissen S, Boots-Sprenger S, Gijsen S, Wesseling P. Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors. J Mol Diagn 2006; 8: 433-43.JeukenJCornelissenSBoots-SprengerSGijsenSWesselingPMultiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumorsJ Mol Diagn200684334310.2353/jmoldx.2006.060012186761516931583Search in Google Scholar
Barker FG 2nd, Chang SM, Larson DA, Sneed PK, Wara WM, Wilson CB, et al. Age and radiation response in glioblastoma multiforme. Neurosurgery 2001; 49: 1288-97; discussion 1297-8.BarkerFG2ndChangSMLarsonDASneedPKWaraWMWilsonCBet alAge and radiation response in glioblastoma multiformeNeurosurgery200149128897discussion 1297-810.1097/00006123-200112000-0000211846927Search in Google Scholar
Mangiola A, Maira G, De Bonis P, Porso M, Pettorini B, Sabatino G, et al. Glioblastoma multiforme in the elderly: a therapeutic challenge. J Neurooncol 2006; 76: 159-63.MangiolaAMairaGDeBonis PPorsoMPettoriniBSabatinoGet alGlioblastoma multiforme in the elderly: a therapeutic challengeJ Neurooncol2006761596310.1007/s11060-005-4711-116132492Search in Google Scholar
Buckner JC.Factors influencing survival in high-grade gliomas. Semin Oncol 2003; 30(6 Suppl 19):10-4.BucknerJCFactors influencing survival in high-grade gliomasSemin Oncol2003306 Suppl 1910410.1053/j.seminoncol.2003.11.03114765378Search in Google Scholar
Orringer D, Lau D, Khatri S, Zamora-Berridi GJ, Zhang K, Wu C, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival. J Neurosurg 2012; 117: 851-9.OrringerDLauDKhatriSZamora-BerridiGJZhangKWuCet alExtent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survivalJ Neurosurg2012117851910.3171/2012.8.JNS1223422978537Search in Google Scholar
Dea N, Fournier-Gosselin MP, Mathieu D, Goffaux P, Fortin D. Does extent of resection impact survival in patients bearing glioblastoma? Can J Neurol Sci 2012; 39: 632-7.DeaNFournier-GosselinMPMathieuDGoffauxPFortinDDoes extent of resection impact survival in patients bearing glioblastoma?Can J Neurol Sci201239632710.1017/S031716710001537722931705Search in Google Scholar
Marina O, Suh JH, Reddy CA, Barnett GH, Vogelbaum MA, Peereboom DM, et al. Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution. Clinical article. J Neurosurg 2011; 115: 220-9.MarinaOSuhJHReddyCABarnettGHVogelbaumMAPeereboomDMet alTreatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution. Clinical articleJ Neurosurg2011115220910.3171/2011.3.JNS1049521548745Search in Google Scholar
Stark AM, van de Bergh J, Hedderich J, Mehdorn HM, Nabavi A. Glioblastoma: clinical characteristics, prognostic factors and survival in 492 patients. Clin Neurol Neurosurg 2012; 114: 840-5.StarkAMvan de BerghJHedderichJMehdornHMNabaviAGlioblastoma: clinical characteristics, prognostic factors and survival in 492 patientsClin Neurol Neurosurg2012114840510.1016/j.clineuro.2012.01.02622377333Search in Google Scholar
Chambless LB, Kistka HM, Parker SL, Hassam-Malani L, McGirt MJ, Thompson RC. The relative value of postoperative versus preoperative Karnofsky Performance Scale scores as a predictor of survival after surgical resection of glioblastoma multiforme. J Neurooncol 2015; 121: 359-64.ChamblessLBKistkaHMParkerSLHassam-MalaniLMcGirtMJThompsonRCThe relative value of postoperative versus preoperative Karnofsky Performance Scale scores as a predictor of survival after surgical resection of glioblastoma multiformeJ Neurooncol20151213596410.1007/s11060-014-1640-x25344883Search in Google Scholar
Li J, Wang M, Won M, Shaw EG, Coughlin C, Curran WJ Jr, et al. Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. Int J Radiat Oncol Biol Phys 2011; 81: 623-30.LiJWangMWonMShawEGCoughlinCCurranWJJret alValidation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastomaInt J Radiat Oncol Biol Phys2011816233010.1016/j.ijrobp.2010.06.012378321120888136Search in Google Scholar
Paravati AJ, Heron DE, Landsittel D, Flickinger JC, Mintz A, Chen YF, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era. J Neurooncol 2011; 104: 339-49.ParavatiAJHeronDELandsittelDFlickingerJCMintzAChenYFet alRadiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide eraJ Neurooncol20111043394910.1007/s11060-010-0499-8315137421181233Search in Google Scholar
Lamborn KR, Chang SM, Prados MD. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol 2004; 6: 227-35.LambornKRChangSMPradosMDPrognostic factors for survival of patients with glioblastoma: recursive partitioning analysisNeuro Oncol200462273510.1215/S1152851703000620187199915279715Search in Google Scholar
Ardebili SY, Zajc I, Gole B, Campos B, Herold-Mende C, Drmota S, Lah TT. CD133/prominin1 is prognostic for GBM patient’s survival, but inversely correlated with cysteine cathepsins’ expression in glioblastoma derived spheroids. Radiol Oncol 2011; 45: 102-15.ArdebiliSYZajcIGoleBCamposBHerold-MendeCDrmotaSLahTTCD133/prominin1 is prognostic for GBM patient’s survival, but inversely correlated with cysteine cathepsins’ expression in glioblastoma derived spheroidsRadiol Oncol2011451021510.2478/v10019-011-0015-6342373122933943Search in Google Scholar
Mesti T, Moltara ME, Boc M, Rebersek M, Ocvirk J. Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience. Radiol Oncol 2015; 49: 80-5.MestiTMoltaraMEBocMRebersekMOcvirkJBevacizumab and irinotecan in recurrent malignant glioma, a single institution experienceRadiol Oncol201549:80510.2478/raon-2014-0021436261125810706Search in Google Scholar
Wang M, Dignam JJ, Won M, Curran W, Mehta M, Gilbert MR. Variation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525. Neuro Oncol 2015; 17: 999-1006.WangMDignamJJWonMCurranWMehtaMGilbertMRVariation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525Neuro Oncol201517999100610.1093/neuonc/nov009565435125688120Search in Google Scholar
Brandes AA, Franceschi E, Ermani M, Tosoni A, Albani F, Depenni R, et al. Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: results from a prospective population-based registry. Could survival differ in a high-volume center? Neurooncol Pract 2014; 1: 166-71.BrandesAAFranceschiEErmaniMTosoniAAlbaniFDepenniRet alPattern of care and effectiveness of treatment for glioblastoma patients in the real world: results from a prospective population-based registry. Could survival differ in a high-volume center?Neurooncol Pract201411667110.1093/nop/npu021436971626034628Search in Google Scholar
Weller M, Tabatabai G, Kästner B. MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial. Clin Cancer Res 2015; 21: 2057-64.WellerMTabatabaiGKästnerBMGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trialClin Cancer Res20152120576410.1158/1078-0432.CCR-14-273725655102Search in Google Scholar
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.HegiMEDiserensACGorliaTHamouMFdeTribolet NWellerMet alMGMT gene silencing and benefit from temozolomide in glioblastomaN Engl J Med2005352997100310.1056/NEJMoa04333115758010Search in Google Scholar
Kim YS, Kim SH, Cho J, Kim JW, Chang JH, Kim DS, et al. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study. Int J Radiat Oncol Biol Phys 2012; 84: 661-7.KimYSKimSHChoJKimJWChangJHKimDSet alMGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution studyInt J Radiat Oncol Biol Phys201284661710.1016/j.ijrobp.2011.12.08622414280Search in Google Scholar
Ogura R, Tsukamoto Y, Natsumeda M, Isogawa M, H, Kobayashi T, et al. Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas. Neuropathology 2015; 35: 324-35.OguraRTsukamotoYNatsumedaMIsogawaM, HKobayashiTet alImmunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomasNeuropathology2015353243510.1111/neup.1219625950388Search in Google Scholar
Lévy S, Chapet S, Mazeron JJ. [Management of gliomas]. [Article in French]. Cancer Radiother. 2014; 18: 461-7.LévySChapetSMazeronJJ[Management of gliomas]. [Article in French]Cancer Radiother201418461710.1016/j.canrad.2014.07.14725201633Search in Google Scholar
